心房分流治疗心力衰竭

IF 2.8 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Alexander M. Spring MD , Andrea Scotti MD , Julio Echarte-Morales MD , Matteo Sturla MD , Manaf Assafin MD , Guillaume Bonnet MD , Lorenzo D’Angelo MD , Juan Torrado MD , Sandhya Murthy MD , Juan F. Granada MD , Edwin Ho MD , Leandro Slipczuk MD, PhD , Ulrich P. Jorde MD , Jozef Bartunek MD, PhD , Azeem Latib MD
{"title":"心房分流治疗心力衰竭","authors":"Alexander M. Spring MD ,&nbsp;Andrea Scotti MD ,&nbsp;Julio Echarte-Morales MD ,&nbsp;Matteo Sturla MD ,&nbsp;Manaf Assafin MD ,&nbsp;Guillaume Bonnet MD ,&nbsp;Lorenzo D’Angelo MD ,&nbsp;Juan Torrado MD ,&nbsp;Sandhya Murthy MD ,&nbsp;Juan F. Granada MD ,&nbsp;Edwin Ho MD ,&nbsp;Leandro Slipczuk MD, PhD ,&nbsp;Ulrich P. Jorde MD ,&nbsp;Jozef Bartunek MD, PhD ,&nbsp;Azeem Latib MD","doi":"10.1016/j.shj.2025.100704","DOIUrl":null,"url":null,"abstract":"<div><div>Despite a plethora of pharmacological therapies for heart failure (HF), reducing the symptomatic burden in patients with advanced HF remains an unmet clinical need. Over the past decade, atrial shunting has emerged as a novel therapy for those with symptomatic HF despite optimal guideline-directed medical therapy. Initially thought of as a therapy reserved for those with diastolic HF, the field now spans the entire HF spectrum. In this review, we explore the physiology, devices, and trials that have shaped the field of atrial shunting. We detail how device-based interatrial shunts, no-implant interatrial shunts, and coronary sinus shunts aim to provide clinical benefit in specific patient populations and the limitations associated with their use.</div></div>","PeriodicalId":36053,"journal":{"name":"Structural Heart","volume":"9 8","pages":"Article 100704"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Atrial Shunting for Heart Failure\",\"authors\":\"Alexander M. Spring MD ,&nbsp;Andrea Scotti MD ,&nbsp;Julio Echarte-Morales MD ,&nbsp;Matteo Sturla MD ,&nbsp;Manaf Assafin MD ,&nbsp;Guillaume Bonnet MD ,&nbsp;Lorenzo D’Angelo MD ,&nbsp;Juan Torrado MD ,&nbsp;Sandhya Murthy MD ,&nbsp;Juan F. Granada MD ,&nbsp;Edwin Ho MD ,&nbsp;Leandro Slipczuk MD, PhD ,&nbsp;Ulrich P. Jorde MD ,&nbsp;Jozef Bartunek MD, PhD ,&nbsp;Azeem Latib MD\",\"doi\":\"10.1016/j.shj.2025.100704\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Despite a plethora of pharmacological therapies for heart failure (HF), reducing the symptomatic burden in patients with advanced HF remains an unmet clinical need. Over the past decade, atrial shunting has emerged as a novel therapy for those with symptomatic HF despite optimal guideline-directed medical therapy. Initially thought of as a therapy reserved for those with diastolic HF, the field now spans the entire HF spectrum. In this review, we explore the physiology, devices, and trials that have shaped the field of atrial shunting. We detail how device-based interatrial shunts, no-implant interatrial shunts, and coronary sinus shunts aim to provide clinical benefit in specific patient populations and the limitations associated with their use.</div></div>\",\"PeriodicalId\":36053,\"journal\":{\"name\":\"Structural Heart\",\"volume\":\"9 8\",\"pages\":\"Article 100704\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Structural Heart\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2474870625002969\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Structural Heart","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2474870625002969","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

尽管对心力衰竭(HF)有大量的药物治疗,但减轻晚期心力衰竭患者的症状负担仍然是一个未满足的临床需求。在过去的十年里,心房分流术已经成为一种治疗症状性心衰的新方法,尽管有最佳的指导药物治疗。最初被认为是为舒张性心衰患者保留的一种治疗方法,现在该领域涵盖了整个心衰频谱。在这篇综述中,我们探讨了形成心房分流领域的生理学、设备和试验。我们详细介绍了基于装置的房间分流、无植入物的房间分流和冠状动脉窦分流是如何在特定患者群体中提供临床益处的,以及它们使用的局限性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Atrial Shunting for Heart Failure
Despite a plethora of pharmacological therapies for heart failure (HF), reducing the symptomatic burden in patients with advanced HF remains an unmet clinical need. Over the past decade, atrial shunting has emerged as a novel therapy for those with symptomatic HF despite optimal guideline-directed medical therapy. Initially thought of as a therapy reserved for those with diastolic HF, the field now spans the entire HF spectrum. In this review, we explore the physiology, devices, and trials that have shaped the field of atrial shunting. We detail how device-based interatrial shunts, no-implant interatrial shunts, and coronary sinus shunts aim to provide clinical benefit in specific patient populations and the limitations associated with their use.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Structural Heart
Structural Heart Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.60
自引率
0.00%
发文量
81
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信